Skip to content

Transcranial Direct Current Stimulation (tDCS) in Pediatric Obsessive Compulsive Disorder (OCD)

Transcranial Direct Current Stimulation (tDCS) Modulation of Neurocognitive Processes Underlying Pediatric Obsessive Compulsive Disorder (OCD)

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04548609
Enrollment
6
Registered
2020-09-14
Start date
2021-01-25
Completion date
2025-03-05
Last updated
2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder, Pediatric Psychiatric Disorder

Keywords

Transcranial Direct Current Stimulation

Brief summary

In this study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in modulating aberrant neurocognitive processes implicated in pediatric patients with obsessive compulsive disorder (OCD).

Detailed description

In this study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in modulating aberrant neurocognitive processes implicated in pediatric patients with obsessive compulsive disorder (OCD). The investigators propose two arms of the study that will investigate fear extinction learning and inhibitory control in one arm (A), and goal orientated versus habit-based behavior and inhibitory control in the other (B). All subjects will undergo three study conditions: two with active tDCS to each of two different brain targets and one under sham tDCS. The order of stimulation (sham or active tDCS) will be randomized.

Interventions

DEVICETranscranial Direct Current Stimulation

In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
10 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

1. Outpatient youth between the ages 10-17 years 2. Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) ≥16 (moderately severe). OCD must be determined to be the primary or co-primary diagnosis using the The Schedule for Affective Disorders and Schizophrenia for School-Age Children- Computer administered version (KSADS-COMP) based on all available information. 3. Child has a full-scale IQ≥85 as assessed on the Wechsler Abbreviated Scale of Intelligence® Second Edition (WASI®-II) (within 90% CI). To decrease participant burden, the WASI®-II will only be conducted in cases of suspected intellectual disability after meeting with the PI. 4. English speaking.

Exclusion criteria

1. Receiving concurrent psychotherapy for subject's OCD (except maintenance).Subjects receiving pre- established concurrent psychotherapy for at least 8 weeks regarding other psychological issues are eligible for enrollment. 2. New Treatments: Initiation of an antidepressant within 12 weeks before study enrollment or an antipsychotic 6 weeks before study enrollment. No new alternative medications, nutritional or therapeutic diets within 6 weeks of study enrolment. 3. Established Treatment changes: Any change in established psychotropic medication (e.g., antidepressants, anxiolytics, stimulant, alpha agonist) within 8 weeks before study enrollment (6 weeks for antipsychotic). Alternative medications must be stable for 6 weeks prior to baseline. Any medications must remain stable during treatment; consistent with the National Institute of Health (NIH)-funded Child Anxiety Multimodal Study (CAMS) trial, downward adjustments due to side effects may be acceptable and will be discussed with the study child and adolescent psychiatrist and the community psychiatrist. 4. Current clinically significant suicidality or individuals who have engaged in suicidal behaviors within 6 months will be excluded and referred for appropriate clinical care. 5. Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for conduct disorder, autism, bipolar, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, schizophrenia or schizoaffective disorders 6. Youth with hoarding symptoms as they may be conceptually and genetically different from other OCD subtypes. 7. BMI less than 18.5. 8. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, ventriculoperitoneal (VP) shunt, pacemakers. 9. Active substance dependence (except for tobacco). 10. Pregnant or nursing females as the effects of tDCS on pregnancy are unknown. 11. Presence of a significant and/or unstable medical illness that might lead to hospitalization during the study.

Design outcomes

Primary

MeasureTime frameDescription
Change in Stop Signal Task50 minutes- 20 minutes before and immediately after a single 30 minute tDCS sessionAbility to Inhibit a Response Task For the stop-signal task, the outcome of inhibitory control is measured by the stop signal reaction time (SSRT), calculated by subtracting the stop signal delay (SSD) from the go signal response time (RT).
Change in Fear Extinction Recall TaskWithin 12-24 hours after the tDCS session the day beforeDegree of recall to a previously extinguished conditioned stimulus.
Change in Model-Based Index on the Two-stage Sequential Reinforcement Learning Task (Sequential Spaceship Task)40 minutes- immediately before and 10 minutes after a 30 minute single tDCS sessionDecision-making task that quantifies the relative contribution of model-based (goal-directed) vs model-free (habit-based) choice strategies. The Model-Based Index, is derived from each participant's probability of repeating their first-stage choice on the following trial, computed separately for four combinations of prior-trial outcome (rewarded or unrewarded) and transition type (common or rare): (stay probability after rewarded-common trials minus stay probability after rewarded-rare trials) plus (stay probability after unrewarded-rare trials minus stay probability after unrewarded-common trials). The index ranges from -2.0 to 2.0. A score near 0 indicates choices driven primarily by recent reward history regardless of transition type (model-free/habit-based responding), while higher positive scores indicate choices that are additionally sensitive to the task's transition structure (model-based/goal-directed responding). Higher scores means greater degree of goal-directed control.

Secondary

MeasureTime frameDescription
Change in EEG Readings90 minutes- 30 minutes before and 30 minutes after a single 30 minute tDCS sessionDegree and type of change in event related potentials (ERPs) amplitudes.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJoan Camprodon, MD, PhD, MPH

Massachusetts General Hospital

PRINCIPAL_INVESTIGATORDaniel Geller, MD

Massachusetts General Hospital

Baseline characteristics

Characteristic
Age, Continuous14.83 years
STANDARD_DEVIATION 1.47
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
5 Participants
Sex: Female, Male
Female
2 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 00 / 00 / 40 / 50 / 4
other
Total, other adverse events
0 / 00 / 00 / 00 / 41 / 50 / 4
serious
Total, serious adverse events
0 / 00 / 00 / 00 / 40 / 50 / 4

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026